Restricted accessReview articleFirst published online 2025-10
Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation
Multiple sclerosis (MS) presents a spectrum of disease activities, making prognostication and treatment challenging. Our focus on aggressive MS (AMS), a subset lacking a universally accepted definition, aims to clarify its identification and management. Here we critically dissect the different criteria for defining AMS based on the latest research and consensus, the early prognostic factors which can unambiguously identify aggressive variants early in the disease course and the available high-efficacy therapies, with a special focus on autologous haematopoietic stem cell transplantation (AHSCT), which is considered a standard of care for relapsing-remitting MS refractory to disease-modifying treatments. The review explores the potential of tailoring AHSCT protocols to individual risk and disease activity profiles, suggesting a personalized approach that could optimize treatment efficacy and safety. While awaiting the results of ongoing randomized clinical trials, AHSCT should be considered for patients with poor prognostic factors early in the disease course, in case of suboptimal response to disease-modifying therapies, but also in naïve patients with AMS experiencing rapid disability accrual.
MalpasCBManouchehriniaASharminandS, et al. Early clinical markers of aggressive multiple sclerosis. Brain2020; 143(5): 1400–1413.
2.
EllenbergerDFlacheneckerPFneishandF, et al. Aggressive multiple sclerosis: A matter of measurement and timing. Brain2020; 143(5): e97.
3.
RodriguezSCouloumeLFerrantJ, et al. Blood immunophenotyping of multiple sclerosis patients at diagnosis identifies a classical monocyte subset associated to disease evolution. Front Immunol2025; 15: 1494842.
4.
TolentinoMPaceFPerantieDC, et al. Cerebrospinal fluid biomarkers as predictors of multiple sclerosis severity. Mult Scler Relat Disord2025; 94: 106268.
5.
International Multiple Sclerosis Genetics Consortium and MultipleMS Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature2023; 619(7969): 323–331.
6.
JokubaitisVGCampagnaMPIbrahimO, et al. Not all roads lead to the immune system: The genetic basis of multiple sclerosis severity. Brain2023; 146(6): 2316–2331.
7.
CalabreseMPreziosaPScalfariA, et al. Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol2024; 96(1): 1–20.
8.
EngelenburgHJvan den BoschAMRChenJQA, et al. Multiple sclerosis severity variant in DYSF-ZNF638 locus associates with neuronal loss and inflammation. Iscience2025; 28: 108154.
9.
LublinFDReingoldSCCohenJA. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83(3): 278–286.
10.
KapposLWolinskyJSGiovannoniG, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol2020; 77(9): 1132–1140.
11.
ScalfariATraboulseeAOhJ, et al. Smouldering-associated worsening in multiple sclerosis: An international consensus statement on definition, biology, clinical implications, and future directions. Ann Neurol2024; 96(5): 826–845.
12.
CorrealeJRushCABarbozaA. Are highly active and aggressive multiple sclerosis the same entity. Front Neurol2023; 14: 1132170.
13.
HardyTATobinWOLucchinettiCF. Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló’s concentric sclerosis. Mult Scler2016; 22(8): 986–992.
14.
GholipourTHealyBBaruchNF, et al. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology2011; 76(23): 1996–2001.
15.
MenonSZhuFShiraniA, et al. Disability progression in aggressive multiple sclerosis. Mult Scler2017; 23(4): 456–463.
16.
TintoreMArrambideGOtero-RomeroS, et al. The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Mult Scler2020; 26(13): 1658–1669.
ScottTFLaforetGYouX. Aggressive relapsing multiple sclerosis characterized by rapid disability progression. Mult Scler Relat Disord2013; 2(4): 370–376.
19.
EdanGComiGLe PageE, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: A 3-year randomised trial. J Neurol Neurosurg Psychiatry2011; 82(12): 1344–1350.
20.
SaccardiRFreedmanMSSormaniMP, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A position paper. Mult Scler2012; 18(6): 825–834.
21.
BoseGHealyBCLokhandeHA, et al. Early predictors of clinical and MRI outcomes using least absolute shrinkage and selection operator (LASSO) in multiple sclerosis. Ann Neurol2022; 92(1): 87–96.
22.
GasperiniCProsperiniLRoviraÀ, et al. Scoring the 10-year risk of ambulatory disability in multiple sclerosis: The RoAD score. Eur J Neurol2021; 28(8): 2533–2542.
23.
BrownleeWJAltmannDRPradosF, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain2019; 142(8): 2276–2287.
24.
MonrealEFernández-VelascoJIÁlvarez-LafuenteR, et al. Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain2024; 147(12): 4084–4093.
25.
Schaller-PauleMAMaiwormMSchäferJH, et al. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury. J Neurol2024; 271(6): 3512–3526.
26.
LauererMWiltgenTBrücknerC, et al. Predictors of early disability accumulation in newly diagnosed multiple sclerosis: Clinical, imaging and cerebrospinal fluid measures. J Neurol Neurosurg Psychiatry17: 335037.
27.
IacobaeusEGeorginaAMaria PiaA, et al. Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Mult Scler2020; 26(10): 1161–1169.
28.
ArrambideGIacobaeusEAmatoMP, et al. Aggressive multiple sclerosis (2): Treatment. Mult Scler2020; 26(10): 1170–1182.
29.
Rae-GrantADayGSMarrieRA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology2018; 90(17): 777–788.
30.
MontalbanXGoldRThompsonAJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler2018; 24(2): 96–120.
31.
HardingKWilliamsOWillisM, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol2019; 76(5): 536–541.
32.
HeAMerkelBBrownJWL, et al. Timing of high-efficacy therapy for multiple sclerosis: A retrospective observational cohort study. Lancet Neurol2020; 19(4): 307–316.
33.
BuronMDChalmerTASellebjergF, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study. Neurology2020; 95(11): e1041–e1051.
34.
SpelmanTKalincikTZhangA, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: Data from 2 different national strategies. JAMA Neurol2021; 78(10): 1197–1204.
35.
IaffaldanoPLucisanoGCaputoF, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord2021; 14: 17562864211019574.
36.
BrownJWLColesAHorakovaD, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA2019; 321(2): 175–187.
37.
UherTKrasenskyJMalpasC, et al. Evolution of brain volume loss rates in early stages of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2021; 8(3).
38.
GiovannoniGLangSWolffR, et al. A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther2020; 9(2): 359–374.
39.
GoldschmidtCMcGinleyMP. Advances in the treatment of multiple sclerosis. Neurol Clin2021; 39(1): 21–33.
40.
SamjooIAWorthingtonEDrudgeC, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res2021; 10(6): 495–507.
41.
ScoldingNBarnesDCaderS, et al. Association of British Neurologists: Revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol2015; 15(4): 273–279.
42.
FilippiMAmatoMPCentonzeD, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: An expert opinion. J Neurol2022; 269(10): 5382–5394.
43.
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354(9): 899–910.
44.
RudickRAStuartWHCalabresiPA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med2006; 354(9): 911–923.
45.
HutchinsonMKapposLCalabresiPA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol2009; 256(3): 405–415.
46.
CohenJAColesAJArnoldDL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380(9856): 1819–1828.
47.
ColesAJTwymanCLArnoldDL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380(9856): 1829–1839.
48.
ColesAJFoxEVladicA, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology2012; 78(14): 1069–1078.
49.
ZiemssenTBassADBerkovichR, et al. Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: Post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study. CNS Drugs2020; 34(9): 973–988.
50.
HauserSLWaubantEArnoldDL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med2008; 358(7): 676–688.
51.
DurozardPMaaroufABoutiereC, et al. Efficacy of rituximab in refractory RRMS. Mult Scler2019; 25(6): 828–836.
52.
HauserSLBarr-OrAComiG, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376(3): 221–234.
53.
TurnerBCreeBACKapposL, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol2019; 266(5): 1182–1193.
54.
HauserSLBarr-OrACohenJA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med2020; 383(6): 546–557.
55.
SteinmanLFoxEHartungH-P, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med2022; 387(8): 704–714.
56.
SharrackBSaccardiRAlexanderT, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: Updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant2020; 55(2): 283–306.
57.
MuraroPAMariottiniAGrecoR, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder – recommendations from ECTRIMS and the EBMT. Nat Rev Neurol2025; 21(3): 140–158.
58.
MariottiniADe MatteisECencioniMT, et al. Haematopoietic stem cell transplantation for the treatment of multiple sclerosis: Recent advances. Curr Neurol Neurosci Rep2023; 23(9): 507–520.
59.
BrittainGColesAJGiovannoniG, et al. Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: What, how, who and why. Pract Neurol2023; 23(2): 139–145.
60.
BoffaGIngleseMMancardiGL. Hematopoietic stem cell transplantation for multiple sclerosis. In: IngleseMMancardiGL (eds) Handbook of Clinical Neurology. Vol 202. New York: Elsevier, 2024, pp. 153–167.
61.
DasJSnowdenJABurmanJ, et al. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis. Mult Scler2021; 27(8): 1198–1204.
62.
BurtRKBalabanovRBurmanJ, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. JAMA2019; 321(2): 165–174.
63.
BoffaGLapucciCSbragiaE, et al. Aggressive multiple sclerosis: A single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. Eur J Neurol2020; 27(10): 2047–2055.
64.
HäußlerVUferFPöttgenJ, et al. aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis. Ann Clin Transl Neurol2021; 8(6): 1269–1278.
65.
ZhukovskyCSandgrenSSilfverbergT, et al. Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: An observational study. J Neurol Neurosurg Psychiatry2021; 92(2): 189–194.
66.
KalincikTSharminSRoosI, et al. Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurol2023; 80(7): 702–713.
67.
MuraroPAZitoASignoriA, et al. Effectiveness of autologous hematopoietic stem cell transplantation versus alemtuzumab and ocrelizumab in relapsing multiple sclerosis: A single center cohort study. Ann Neurol. Published Online. doi:10.1002/ana.26730
68.
IngleseMCohenJASharrackB, et al. Chapter 20 – Ongoing randomized clinical trials on HSCT in multiple sclerosis. In: IngleseMMancardiGL (eds) Handbook of Clinical Neurology. Vol 202. New York: Elsevier, 2024, pp. 307–315.
69.
BurtRKFargeDSaccardiR, et al. Autologous HSCT conditioning regimens for autoimmune diseases. In: BurtRKFargeDRuizMA, et al. (eds) Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases. Boca Raton, FL: CRC Press, 2021, p. 204–212.
70.
BurtRKFargeDRuizMA, et al. Late toxicity and supportive care of patients undergoing hematopoietic cell transplantation for autoimmune diseases. In: BurtRKFargeDRuizMA, et al. (eds) Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases. Boca Raton, FL: CRC Press, 2021, p. 252–263.
71.
BoffaGMassacesiLIngleseM, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology2021; 96: e1215–e1226.
72.
NicholasRSRhoneEEMariottiniA, et al. Autologous hematopoietic stem cell transplantation in active multiple sclerosis: A real-world case series. Neurology2021; 97(9): e890–e901.
73.
SilfverbergTZjukovskajaCLjungmanP, et al. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: An observational cohort study. J Neurol Neurosurg Psychiatry2024; 95: 125–133.
74.
BurtRKCohenBARussellE, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: Failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood2003; 102(7): 2373–2378.
75.
BowenJDKraftGHWundesA, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: Long-term results. Bone Marrow Transplant2012; 47(7): 946–951.
76.
SamijnJPte BoekhorstPAMondriaT, et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry2006; 77(1): 46–50.
77.
AtkinsHLBowmanMAllanD, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicentre single-group phase 2 trial. Lancet2016; 388(10044): 576–585.
78.
SnowdenJASaccardiRAllezM, et al. Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant2012; 47(6): 770–790.
MooreJJMasseyJCFordCD, et al. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. J Neurol Neurosurg Psychiatry2019; 90(5): 514–521.
81.
TolfAFagiusJCarlsonK, et al. Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation. Acta Neurol Scand2019; 140(5): 320–327.
82.
NashRAHuttonGJRackeMK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology2017; 88(9): 842–852.
83.
BurmanJIacobaeusESvenningssonA, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: The Swedish experience. J Neurol Neurosurg Psychiatry2014; 85(10): 1116–1121.
84.
MariottiniAMarchiLInnocentiC, et al. Intermediate-intensity autologous hematopoietic stem cell transplantation reduces serum neurofilament light chains and brain atrophy in aggressive multiple sclerosis. Front Neurol2022; 13: 820256.
85.
BurtRKHanXQuigleyK, et al. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. J Neurol2022; 269(5): 2513–2526.
86.
MuraroPAMartinRMancardiGL, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol2017; 13(7): 391–405.
87.
SnowdenJABadoglioMLabopinM, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv2017; 1(27): 2742–2755.
88.
AlexanderTGrecoR. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: Overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant2022; 57(7): 1055–1062.
89.
SaccardiR. The 50th annual meeting of the European society for blood and marrow transplantation: Physicians – oral session (O009-O154). Bone Marrow Transplant2024; 59(Suppl. 1): 20–139.
90.
SilfverbergTZjukovskajaCNouiY, et al. BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis. Bone Marrow Transplant2024; 59(8): 1601–1610.
91.
Curro’DVuoloLGualandiF, et al. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. Mult Scler2015; 21(11): 1423–1430.
92.
Peffault de LatourRRisitanoADufourC. Severe aplastic anemia and PNH. In: CarrerasEDufourCMohtyM, et al. (eds) The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. New York: Springer, 2019, pp. 579–585.
93.
VisweswaranMHendrawanKMasseyJC, et al. Sustained immunotolerance in multiple sclerosis after stem cell transplant. Ann Clin Transl Neurol2022; 9(2): 206–220.
94.
HendrawanKKhooMLMVisweswaranM, et al. Long-term suppression of circulating proinflammatory cytokines in multiple sclerosis patients following autologous haematopoietic stem cell transplantation. Front Immunol2021; 12: 782935.
95.
MasseyJVisweswaranMKhooM, et al. Detailed immunophenotyping of the hematopoietic graft from patients with multiple sclerosis undergoing autologous hematopoietic stem cell transplant. Cytotherapy2023; 25(12): 1271–1276.
96.
MasseyJJacksonKSinghM, et al. Haematopoietic stem cell transplantation results in extensive remodelling of the clonal T cell repertoire in multiple sclerosis. Front Immunol2022; 13: 798300.
97.
HamerschlakNRodriguesMMoraesDA, et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant2010; 45(2): 239–248.
98.
BurtRKFargeDRuizMA, et al. Early toxicity and supportive care of HSCT for autoimmune diseases. In: BurtRKFargeDRuizMA, et al. (eds) Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases. Boca Raton, FL: CRC Press, 2021, pp. 241–251.
99.
RobertsFHobbsHJessopH, et al. Rehabilitation before and after autologous haematopoietic stem cell transplantation for patients with multiple sclerosis: Consensus guidelines and recommendations. Front Neurol2020; 11: 556141.
100.
BurtRKMuraroPAFargeD, et al. New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant2021; 56(7): 1509–1517.
101.
AlpingPBurmanJLyckeJ, et al. Safety of alemtuzumab and autologous hematopoietic stem cell transplantation compared to noninduction therapies for multiple sclerosis. Neurology2021; 96(15): e1574–e1584.
102.
LeeHNakamuraKNarayananS, et al. Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis. Mult Scler2018; 24(8): 1055–1066.
103.
RoccatagliataLRoccaMValsasinaP, et al. The long-term effect of AHSCT on MRI measures of MS evolution: A five-year follow-up study. Mult Scler2007; 13(8): 1068–1070.
104.
KvistadSASLehmannAKTrovikLH, et al. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Mult Scler2020; 26(14): 1889–1897.
105.
ChattertonSWithersBSuttonIJ, et al. Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis. Mult Scler2021; 27(13): 2112–2115.
106.
MassarottiCSbragiaEBoffaG, et al. Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis. Mult Scler2021; 27(13): 2103–2107.
107.
SaloojaNSzydloRMSocieG, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: A retrospective survey. Lancet2001; 358(9278): 271–276.
108.
LorenAWChowEJacobsohnDA, et al. Pregnancy after hematopoietic cell transplantation: A report from the late effects working committee of the CIBMTR. Biol Blood Marrow Transplant2011; 17(2): 157–166.
109.
MuraroPAPasquiniMAtkinsHL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol2017; 74(4): 459–469.
110.
MehraVRhoneEWidyaS, et al. Epstein-Barr virus and monoclonal gammopathy of clinical significance in autologous stem cell transplantation for multiple sclerosis. Clin Infect Dis2019; 69(10): 1757–1763.
111.
SaccardiR. The 48th annual meeting of the European society for blood and marrow transplantation: Physicians – oral sessions (O009–O155). Bone Marrow Transplant2022; 57(Suppl1): 16–99.
112.
ShiKLiHChangT, et al. Bone marrow hematopoiesis drives multiple sclerosis progression. Cell2022; 185(13): 2234–2247; e17.
113.
MariottiniAMuraroPASaccardiR. Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis. Mult Scler Relat Disord2023; 78: 104932.
